Amyotrophic Lateral Sclerosis Serum

About Amyotrophic Lateral Sclerosis Serum

Amyotrophic Lateral Sclerosis Serum for Neurodegeneration Research

Our Human ALS Serum is sourced from IRB-consented donors clinically diagnosed with amyotrophic lateral sclerosis (ALS). Each sample is processed and frozen within 24 hours of collection to preserve neuronal injury proteins and other circulating analytes. Serum is acellular, so this product supports soluble-analyte work rather than cellular assays.

ALS Pathobiology and What Serum Reports On

ALS is a progressive neurodegenerative disease of upper and lower motor neurons, not an autoimmune disease. It causes progressive weakness, muscle atrophy, and eventually respiratory failure, and shares a pathological and genetic spectrum with frontotemporal dementia:

• TDP-43 proteinopathy. Cytoplasmic mislocalisation and aggregation of TDP-43 is the defining neuropathological feature in the great majority of ALS cases
• Defined genetic causes include the C9orf72 hexanucleotide repeat expansion, and mutations in SOD1, FUS, and TARDBP; genotype increasingly determines trial eligibility and mechanism-specific therapy
• Neurofilament light chain is the best-supported fluid biomarker in ALS, reflecting axonal injury; phosphorylated neurofilament heavy chain is studied alongside it. Both are measurable in serum by ultrasensitive immunoassay
• Clinical heterogeneity is substantial — bulbar versus limb onset, rate of decline measured on the ALSFRS-R, and survival vary widely, so serum studies benefit from clinically stratified cohorts
• Additional research analytes include creatinine and creatine kinase as indices of muscle mass and injury, and inflammatory mediators reflecting the secondary neuroinflammatory response
• Why serum: a clotting-independent matrix suits ultrasensitive protein immunoassays, multiplex panels, proteomics, and metabolomics, with high aliquot counts and, where available, serial timepoints from the same donor

Donor Stratification Available

• Site of onset: bulbar, upper limb, lower limb, or respiratory
• Familial versus sporadic disease, and known genotype where clinically tested
• Disease duration since symptom onset and since diagnosis
• Functional status and rate of progression where ALSFRS-R scores are documented
• Treatment status, including riluzole, edaravone, or gene-targeted therapy
• Respiratory support status, age, sex assigned at birth, and race/ethnicity
• Matched, age-matched healthy controls available

Product Features

• Collected from clinically confirmed amyotrophic lateral sclerosis donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• Standard and custom aliquot volumes available
• Serial collections from the same donor available on request
• IRB-approved protocols with documented consent

De-identified Donor Data

• Diagnosis confirmation, including site of onset where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported medical history and comorbidities
• Disease duration, functional status, and medication history available on request

Applications

• Neurofilament light chain and pNfH measurement and assay validation
• Biomarker discovery for diagnosis, prognosis, and rate of progression
• Pharmacodynamic biomarker development for gene-targeted and small-molecule therapies
• Serum proteomic and metabolomic profiling
• Neuroinflammatory mediator and cytokine panels
• Longitudinal progression studies using serial timepoints
• Comparative studies against age-matched controls and other neurodegenerative cohorts
• Immunoassay platform development for ultrasensitive neuronal injury markers

Other Amyotrophic Lateral Sclerosis Specimen Types

• Amyotrophic Lateral Sclerosis Plasma — anticoagulated matrix, widely used for NfL assays
• Amyotrophic Lateral Sclerosis Whole Blood — fresh, for germline genotyping and same-day cellular assays
• Amyotrophic Lateral Sclerosis PBMC — cryopreserved cells for transcriptomics and iPSC derivation
• Human Cerebrospinal Fluid — for CNS-proximal biomarker work

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering and Customization

Amyotrophic lateral sclerosis serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For healthy-donor controls and the full specimen range, see our human serum collection.